Table 1.
Patients’ socio-demographic and clinical characteristics at baseline
| Characteristicsa | PAS (N = 70) | Interviewed patients (N = 19) |
|---|---|---|
| Sex, n (%) | ||
| Male | 52 (74.3%) | 15 (78.9%) |
| Female | 18 (25.7%) | 4 (21.1%) |
| Age, years | ||
| Mean (SD) | 70.2 (11.2) | 72.2 (8.2) |
| Median | 73.0 | 72.0 |
| 95% CI | 67.5–72.9 | 68.3–76.2 |
| Region, n (%) | ||
| North America | 40 (57.1%) | 17 (89.5%) |
| Europe | 22 (31.4%) | 2 (10.5%) |
| Rest of the world | 8 (11.4%) | 0 (0.0%) |
| ECOG PS at baseline (n, %) | ||
| 0 | 38 (54.3%) | 10 (52.6%) |
| 1 | 32 (45.7%) | 9 (47.4%) |
| Site of primary tumor (n, %) | ||
| Non-skin | 9 (12.9%) | 4 (21.1%) |
| Skin | 55 (78.6%) | 14 (73.7%) |
| Missing | 6 (8.6%) | 1 (5.3%) |
| Tumor size at baseline (mm) | ||
| n (missing) | 61 (9) | 16 (3) |
| Mean (SD) | 103.7 (79.7) | 83.3 (49.9) |
| Median | 83.0 | 78.5 |
| 95% CI | 83.3–124.1 | 56.7–109.8 |
| Time since initial diagnosis (years) | ||
| Mean (SD) | 2.2 (0.8) | 2.3 (0.8) |
| Median | 2.0 | 2.0 |
| 95% CI | 2.0–2.4 | 2.0–2.7 |
| Time since first metastatic disease (months) | ||
| Mean (SD) | 16.9 (23.4) | 16.3 (10.4) |
| Median | 9.5 | 14.0 |
| 95% CI | 11.4–22.5 | 11.3–21.2 |
| Number of previous therapy lines (n, %) | ||
| Mean (SD) | 1.5 (0.7) | 1.3 (0.5) |
| Median | 1.0 | 1.0 |
| 95% CI | 1.3–1.6 | 1.1–1.6 |
CI confidence interval, ECOG PS Eastern Cooperative Oncology Group performance status, PAS PRO analysis set, SD standard deviation
ECOG PS: 0 = fully active; 1 = restricted in physically strenuous activity
aMissing data included in calculation of percentages